



© Salzburg Tourismus, Foto: Breitegger Ginter



THE 8TH LONDON-INNSBRUCK COLLOQUIUM ON STATUS EPILEPTICUS AND ACUTE SEIZURES

17-20 SEPTEMBER, 2022
SALZBURG, AUSTRIA

FINAL PROGRAMME

WWW.STATUSEPILEPTICUS.EU

Our academic partners are:



PATRONS

Paracelsus Medical University (PMU)
 Strubergasse 21
 5020 Salzburg
 Austria

Christian Doppler University Hospital
 Ignaz-Harrer-Strasse 79
 5020 Salzburg
 Austria

University College London
 UCL Queen Square Institute of
 Neurology
 Queen Square
 London WC1N 3BG
 United Kingdom

EpiCARE
 Hôpital Femme Mère Enfant (HFME)
 59 Boulevard Pinel
 69677 Bron
 France

Karl Landsteiner Institute for
 Neurorehabilitation and Space
 Neurology
 Ignaz-Harrer-Strasse 79
 5020 Salzburg
 Austria

ILAE EUROPE
 c/o International League Against
 Epilepsy
 Suite 105, The Crescent Building,
 Northwood, Dublin D09 C6X8
 Ireland

CHAIRS

Eugen Trinka, Austria
 Simon Shorvon, United Kingdom
 Matthew Walker, United Kingdom

Welcome	4
Information for speakers	6
Information for poster presenters	7
Pre-Colloquium cEEG course	9
Scientific programme	12
Sunday, September 18 th , 2022	12
Monday, September 19 th , 2022	14
Tuesday, September 20 th , 2022	16
List of faculty	19
List of posters	28
Sponsors and exhibitors	51
Social programme	52
General information	53
Notes	56

DEAR COLLEAGUES

It is our greatest pleasure to welcome you to the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures. These meetings have been held every two years since 2007, and the series has become a landmark meeting in the international epilepsy calendar. Due to the COVID-19 pandemic we had to postpone the meeting which was planned for 2021 and are now happy to welcome you back for an in-person meeting in Salzburg.

We have put together an exciting programme with a top-international faculty. There have been major advances in the field over the past years regarding better mechanistic understanding and new treatments, as well as clinical strategies. In addition, it is our greatest pleasure to welcome you to the 2nd European Course on continuous EEG in intensive care. This rapidly emerging field deserves further attention in education and implementation of this valuable diagnostic tool.

We cordially welcome you to the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures as well as the Pre-Colloquium Course on continuous EEG monitoring in ICU's in Salzburg!

With best regards,

Eugen Trinka, Simon Shorvon and Matthew Walker
(Co-Chairs of the London-Innsbruck Colloquium)



Eugen Trinka



Simon Shorvon



Matthew Walker

BISHER
UNERREICHTE
RATEN AN
ANFALLSFREIHEIT

bei Patienten mit unzureichend
kontrollierter fokaler Epilepsie^{1-6,*,†}

ONTOZRY[®]
Cenobamat



JETZT.

Der Neustart für Ihre Patienten
mit dem Ziel der Anfallsfreiheit.



1. Krauss GL et al., Lancet Neurol. 2020; 19(11):38-48. | 2. Gil-Nagel et al., Epilepsia. 2013 Jan;54(1):98-107. | 3. Klein et al., Epilepsia. 2015 Dec;56(12):1890-1898. | 4. Chung et al., CNS Drugs 2010; 24(12):1041-1054. | 5. Steinhoff et al., Epilepsia. 54(8):1481-1489, 2013. | 6. Lattanzi S et al., Drugs. 2022 Feb;82(2):199-218. | * Obgleich keine direkten Vergleichsdaten vorliegen, scheinen die gemeldeten Anfallsfreiheitsraten unter ONTOZRY[®] + Standardtherapie in randomisierten, placebo-kontrollierten Studien mit Patienten mit unzureichend kontrollierter Epilepsie höher zu sein, als in Studien mit anderen antikonvulsiven Medikamenten. | † im Vergleich zu Placebo + Standardtherapie.

Fachkurzinformation: Ontozry 12,5 mg Tabletten, Ontozry 25 mg, 50 mg, 100 mg, 150 mg, 200 mg Filmtabletten Qualitative und quantitative Zusammensetzung: Wirkstoffe: Jede Tablette enthält 12,5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg Cenobamat. Liste der sonstigen Bestandteile: Tablette und Kern der Filmtablette: Lactose Monohydrat, Magnesiumstearat (Ph.Eur.) [pflanzlich] (E470b), Mikrokristalline Cellulose (E460), Hochdisperses Siliciumdioxid (E551), Carboxymethylstärke-Natrium (Typ A) (Ph.Eur.), Ethylbutyrat; 25 mg und 100 mg Filmtabletten: Indigocarmine-Aluminiumsulfid (E132), Eisen(III)-oxid (E172), Eisen(III)-hydroxid-oxid x H₂O (E172), Macrogol 4000, Polyvinylalkohol (E1203), Talkum (E553b), Titandioxid (E171), 50 mg Filmtabletten: Eisen(III)-hydroxid-oxid x H₂O (E172), Macrogol 4000, Polyvinylalkohol (E1203), Talkum (E553b), Titandioxid (E171). Anwendungsbereiche: Ontozry wird angewendet zur adjuvanten Behandlung fokaler Anfälle mit oder ohne sekundäre Generalisierung bei erwachsenen Patienten mit Epilepsie, die trotz einer vorangegangenen Behandlung mit mindestens 2 antiepileptischen Arzneimitteln nicht ausreichend kontrolliert sind Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 genannten sonstigen Bestandteile, familiäres Short-QT-Syndrom (siehe Abschnitt 4.4), Pharmakotherapeutische Gruppe: Antiepileptika, andere Antiepileptika, ATC-Code: N03AX25, Inhaber der Zulassung: Angelini Pharma S.p.A., Viale Amelia 70, 00181, Rom - Italien, Stand der Information: Oktober 2021, Verschreibungspflicht/Apothekenpflicht: Rezept- und apothekspflichtig, Angaben zu besonderen Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit und Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation.

INFORMATION FOR SPEAKERS

Please make sure to bring your PowerPoint presentation on a USB-stick to the MEDIA CHECK at Salzburg Congress 2 hours prior to the start of your session.

Do not bring your own laptop for the presentation. In case your presentation contains video sequences, please ensure to pack them with a standard codec and do not store them in a Quick Time format since this may not be compatible with PowerPoint presentations.

In order to be able to keep the time schedule, please make sure not to exceed the allotted speaking time.

Disclosure of potential conflicts of interest

Speakers at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures are requested to disclose their potential conflicts of interest. Consequently, a conflict of interest statement should be included on your first slide.

Opening hours media check:

Sunday, September 18 th , 2022:	08:30 - 17:00
Monday, September 19 th , 2022:	08:00 - 18:00
Tuesday, September 20 th , 2022:	08:00 - 17:00

INFORMATION FOR POSTER PRESENTERS

POSTER FORMAT:

Please bring your poster in **portrait style**. Poster measures must not exceed A0 format (84,1 cm / 33,11" in width and 118,9 cm / 46,8" in height). No other formats are allowed! Posters exceeding the above-mentioned directions cannot be displayed. Mounting material will be provided on site.

All posters should be displayed during the entire Colloquium and mounted on Sunday, September 18th in the morning. They have to be taken down on Tuesday, September 20th by the end of the Colloquium. All posters not taken down by then will be discarded. Mounting material will be provided on site.

POSTER DISCUSSION:

There are time slots explicitly dedicated to the posters every day. The dates and times are scheduled as follows:

Monday, September 19 th , 2022:	13:30 - 14:30
Tuesday, September 20 th , 2022:	12:40 - 14:00

During these times, you or one of your co-authors should be at your poster site and be prepared to answer questions.

Jazz Pharmaceuticals has been at the forefront of providing therapies and support for our patients living with serious, debilitating neurological disorders.



With the acquisition of GW Pharmaceuticals, the leader in cannabinoid science, we have expanded and diversified our growing neuroscience pipeline. Our purpose is to innovate to transform the lives of patients and their families and we are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options; and we continue to expand our reach and capabilities to discover and develop new therapies that can help people redefine what is possible in their lives.

**PROGRAMME TEACHING COURSE
CONTINUOUS EEG IN ICU**

SATURDAY, SEPTEMBER 17TH 2022

- 09.10 – 17.30** Pre-Colloquium teaching course
Continuous EEG in ICU
Chairs: Eugen Trinka (Salzburg, Austria), Lawrence J. Hirsch (New Haven, USA), Matthew Walker (London, UK)
- 09.00 – 09.10** **Introduction**
Eugen Trinka (Salzburg, Austria)
- 09.10 – 11.10** **Session 1: The basics of neurophysiology in Status epilepticus**
- 09.10 – 09.40 Overview: from EEG-criteria to impact of burden
Eugen Trinka (Salzburg, Austria)
- 09.40 – 10.10 Status epilepticus and ACNS terminology
Markus Leitinger (Salzburg, Austria)
- 10.10 - 10.40 The Ictal-Interictal Continuum (including ACNS terminology)
Nicolas Gaspard (Brussels, Belgium)
- 10.40 - 11.10 The concept of encephalopathy: PROs and CONs
Peter W. Kaplan (Baltimore, USA)
- 11.10 – 11.30** **Coffee break**

11.30 – 13.00 Session 2: Neurophysiology in special cases

- 11.30 – 12.00 Postanoxic coma: do different subgroups need different approaches?
Michel van Putten (Twente, Netherlands)
- 12.00 – 12.30 Management of NORSE/ FIRES
Lawrence J. Hirsch (New Haven, USA)
- 12.30 – 13.00 How it impacts patient management: Examples of superrefractory SE and cEEG
Tom Bleck (Chicago, USA)

13.00 – 14.00 Lunch break

14.00 – 15.30 Session 3: The pediatric point of view

- 14.00 - 14.30 Pediatric Status epilepticus
Susan Byrne (Dublin, Ireland)
- 14.30 - 15.00 ICU EEG-monitoring in Children, including ACNS guidelines
Nicholas N. Abend (Philadelphia, USA)
- 15.00 – 15.30 ICU EEG-monitoring in Neonates, including ACNS guidelines
Ronit Pressler (London, UK)

15.30 – 15.50 Coffee break

15.50 – 17.20 Session 4: The impact on patient management

- 15.50 – 16.20 How it impacts patient management: Examples of Multimodal Monitoring in ICU
Raimund Helbok (Innsbruck, Austria)
- 16.20 - 16.50 Applications of Quantitative EEG in the management of stroke
Raimund Helbok (Innsbruck, Austria)
- 16.50 – 17.20 How can we make life easier? Rapid EEG and computer assistance in the emergency department and ICUs
Lawrence J. Hirsch (Greenwich, USA)

17.20 – 17.30 Summary and future

Eugen Trinko (Salzburg, Austria), Lawrence J. Hirsch (New Haven, USA), Matthew Walker (London, UK)

**PROGRAMME 8TH LONDON-INNSBRUCK
COLLOQUIUM ON STATUS EPILEPTICUS AND
ACUTE SEIZURES**

SUNDAY, SEPTEMBER 18TH 2022

- 10.00 – 10.45 Introduction**
Eugen Trinkka (Salzburg, Austria), Simon Shorvon (London, UK), Matthew Walker (London, UK)
- Opening and ILAE address
Helen Cross (London, UK)
- Surviving Status epilepticus – The patient and family perspective
Nora Wong (Summit, USA)
- 10.45 – 12.45 Session 1: Making the most of what we have**
Chairs: Vincent Navarro (Paris, France),
Nichola Specchio (Rome, Italy)
- 10.45 - 11.25 What have we learned from Randomised Controlled Trials?
Robert Silbergleit (Ann Arbor, USA)
- 11.25 – 12.05 Making SENSE of what we do - How to bring evidence to clinical practice?
Christoph Kellinghaus (Osnabrück, Germany)
- 12.05 – 12.45 Phenobarbital: Rediscovering an effective treatment
Eugen Trinkka (Salzburg, Austria)
- 12.45 – 14.05 Lunch break**

14.05 – 14.20 Industry sponsored talk: Marinus Pharmaceuticals

Clinical Development of Ganaxolone for Status Epilepticus
Joseph Hulihan (Radnor, USA)

14:30 – 15:30 Clinically Meaningful Approaches to Seizure Emergencies



Inspired by patients. supported by UCB
Driven by science.

Chair: Eugen Trinkka (Salzburg, Austria)

Clinically Meaningful Approaches to Seizure Emergencies
Reetta Kälviäinen (Kuopio, Finland)

15.30 – 16.00 Coffee break

16.00 – 18.40 Session 2: Modifying outcomes of Status epilepticus

Chairs: Peter Kaplan (Baltimore, USA),
Tom Bleck (Chicago, USA)

16.00 – 16.40 Have we improved the outcome of Status epilepticus over the past decades?
Aidan Neligan (London, UK)

16.40 - 17.20 Why do people die from Status epilepticus and should we let them in some circumstances?
Reetta Kälviäinen (Kuopio, Finland)

17.20 – 18.00 Understanding pathophysiology and improving outcomes in Electrical Status epilepticus during Sleep (ESES)
Guido Rubboli (Dianalund, Denmark)

18.00 – 18.20 How can we prevent epileptogenesis after Status epilepticus?
Asla Pitkänen (Kuopio, Finland)

18.40 Get-together

MONDAY, SEPTEMBER 19TH 2022**08.50 – 10.50 Session 3: Between Scylla and Charybdis: Harms and benefits of NICU Treatments**

Chairs: Ilo Leppik (Minneapolis, USA),
Tom Bleck (Chicago, USA)

08.50 – 09.30 Balancing risks and benefits of anaesthetics in Status epilepticus
Raoul Sutter (Basel, Switzerland)

09.30 – 10.10 Neuroimaging of Status epilepticus – Making the invisible visible
Pilar Bosque Varela (Salzburg, Austria/Santander, Spain)

10.10 – 10.50 The role of biomarkers in Status epilepticus
Sara Hocker (Rochester, USA)

10.50 – 11.20 Coffee break *kindly supported by* **ceribell**[®]

11.20 – 13.30 Session 4: Pediatric Status epilepticus

Chairs: Ronit Pressler (London, UK),
Barbara Plecko (Graz, Austria)

11.20 - 12.10 NORSE- a useful Clinical Entity to acknowledge or disease mongering?
PRO: Nicolas Gaspard (Brussels, Belgium)
CON: Simon Shorvon (London, UK)

12.10 - 12.50 Prevention of pediatric convulsive Status epilepticus
Tobias Loddenkemper (Boston, USA)

12.50 – 13.30 Challenges of Status epilepticus in rare epilepsies
Renzo Guerrini (Florence, Italy)

13.30 - 14.30 Lunch break and poster discussion

14.30 – 15.00 **Session 5: Key Note Lecture**
Chairs: Eugen Trinko (Salzburg, Austria),
Simon Shorvon (London, UK), Matthew Walker (London, UK)

50 years of Status epilepticus research

Claude Wasterlain (Los Angeles, USA)

15.00 – 15.40 Session 6: Modelling of Status epilepticus – beyond rodents

Chairs: Eva Rohde (Salzburg, Austria),
Gerhard Kluger (Vogtareuth, Germany)

15.00 – 15.40 The Virtual Brain and Status epilepticus
Christophe Bernard (Marseille, France)

15.40 – 16.10 Coffee break

16.10 – 18.10 Session 7: New antiseizure medicines for Status epilepticus

Chairs: Meir Bialer (Jerusalem, Israel),
Annamaria Vezzani (Milan, Italy)

16.10 - 16.50 Brivaracetam or levetiracetam in Status epilepticus? Lessons from a photosensitivity model
Dorothee Kasteleijn-Nolst Trenité (Utrecht, Netherlands)

16.50 - 17.30 Antioxidants in Status epilepticus
Matthew Walker (London, UK)

17.30 – 17.50 2DG for treatment of Status epilepticus and acute repetitive seizures
Thomas Sutula (Wisconsin, USA)

17.50 - 18.10 Update on neuroactive steroids in the treatment of Status epilepticus
Mike Rogawski (Sacramento, USA)

19.00 Colloquium Dinner

TUESDAY, SEPTEMBER 20TH 2022

- 08.50 – 10.50 Session 8: Neurophysiology of Status epilepticus**
Chairs: Markus Leitinger (Salzburg, Austria),
Michel van Putten (Enschede, Netherlands)
- 08.50 - 09.30 Spreading depolarizations, seizures and epilepsy
Jens Dreier (Berlin, Germany)
- 09.30 – 10.10 Lessons from the TELSTAR Trial
Michel van Putten (Enschede, Netherlands)
- 10.10 – 10.50 Neuroimmunology of Status epilepticus
Annamaria Vezzani (Milan, Italy)
- 10.50 – 11.20 Coffee break *kindly supported by* **ceribell**[®]
- 11.20 – 12.40 Session 9: Predicting outcome**
Chairs: Francesco Brigo (Meran, Italy),
Felix Rosenow (Frankfurt, Germany)
- 11.20 - 12.00 Do clinical features or EEG in the acute setting predict the
long-term outcome?
Lawrence J. Hirsch (New Haven, USA)
- 12.00 – 12.40 Clinical clusters and outcomes in Status epilepticus
Simona Lattanzi (Ancona, Italy)
- 12.40 – 14.00 Lunch break and poster discussion

- 14.00 - 16.00 **Session 10: Novel approaches to diagnosis and
treatment I**
Chairs: Nathan Fountain (Charlottesville, USA),
Mike Rogawski (Sacramento, USA)
- 14.00 – 14.40 Rapid emergency EEG
Josef Parvizi (Stanford, USA)
- 14.40 – 15.20 Why Ketamine?
Jaideep Kapur (Charlottesville, USA)
- 15.20 – 16.00 Status epilepticus in pregnancy
Felix Rosenow (Frankfurt, Germany)
- 16.00 – 16.30 Coffee break
- 16.30 – 17.50 Session 11: Novel approaches to diagnosis and
treatment II**
Chairs: Dimitri Kullmann (London, UK), Andrew Cole, (Boston, USA)
- Disclaimer:
This symposium has been financially supported by GW Pharmaceuticals, part of
Jazz Pharmaceuticals. GW/Jazz pharmaceuticals have had no involvement in the
development, content or organisation of this symposium.
- 16.30 - 17.10 Intravenous Topiramate
Wolfgang Löscher (Hannover, Germany)
- 17.10 – 17.50 Repurposing of cholesterol lowering agents in Status
epilepticus
Aurélie Hanin (Paris, France)
- 17.50 – 18.00 Closing Remarks**
Eugen Trinko (Salzburg, Austria), Simon Shorvon
(London, UK), Matthew Walker (London, UK)



*Through commitment,
innovation, and community,
Marinus is dedicated
to the development of
treatments for status
epilepticus and
rare epilepsies*

To learn more, please visit us in the Exhibit Hall at Table #1
Or email us at medicalaffairs@marinuspharma.com



Commitment



Innovation



Community

Abend, Nicholas, Dr.

CHOP/University of Pennsylvania
Department of Neurology and Pediatrics
Philadelphia, USA
abend@email.chop.edu

Bernard, Christophe, Ph.D

Aix-Marseille Université
Institut de Neurosciences des Systèmes
Marseille, France
christophe.bernard@univ-amu.fr

Bialer, Meir, Prof.

Bialer Meir, Prof.
The Hebrew University of Jerusalem
Department of Pharmaceutics
Jerusalem, Israel
meirb@ekmd.huji.ac.il

Bleck, Thomas, Prof.

Northwestern University
Department of Neurology
Chicago, USA
tbleck@northwestern.edu

Bosque Varela, Pilar, Dr.

Uniklinikum Salzburg
Department of Neurology
Salzburg, Austria
pi.bosque-varela@salk.at

Brigo, Francesco, Prof.

Hospital of Merano
Department of Neurology
Meran, Italy
dr.francescobrigo@gmail.com

Byrne, Susan, Dr.

Royal College of Surgeons in Ireland and Children's Health Ireland
 Department of Futureneuro and Paediatric Neurology
 Dublin, Ireland
 suabyrne@rcsi.ie

Cole, Andrew J., Prof.

Harvard Medical School
 Fruit Street, Wang ACC 739 L
 Boston, United States
 cole.andrew@mgh.harvard.edu

Cross, Helen, Prof.

UCL – Institute of Child Health
 Department of Clinical Neurosciences
 London, UK
 h.cross@ucl.ac.uk

Dreier, Jens, Prof.

Charité Universitätsmedizin Berlin
 Center for Stroke Research Berlin
 Berlin, Germany
 jens.dreier@charite.de

Fountain, Nathan, Dr.

University of Virginia
 Charlottesville, United States
 nbf2p@hscmail.mcc.virginia.edu

Gaspard, Nicolas, Dr.

Université Libre de Bruxelles - Hôpital Universitaire de Bruxelles -
 Hôpital Erasme
 Department of Neurology
 Brussels, Belgium
 Nicolas.Gaspard@erasme.ulb.ac.be

Guerrini, Renzo, Prof.

Meyers Children Hospital
 Department of Neuroscience
 Florence, Italy
 renzo.guerrini@meyer.it

Hanin, Aurelie, Dr.

Pitié-Salpêtrière Hospital / Yale School of Medicine
 Department of Neurology
 Paris, France
 aurelie.hanin@icm-institute.org

Helbok, Raimund, Dr.

Medizinische Universität Innsbruck
 Department of Neurology
 Innsbruck, Austria
 raimund.helbok@tirol-kliniken.at

Hirsch, Lawrence J., Dr.

Yale School of Medicine
 Department of Neurology
 Greenwich, USA
 lawrence.hirsch@yale.edu

Hocker, Sara, Prof.

Mayo Clinic
 Department of Neurology
 Rochester
 hocker.sara@mayo.edu

Kälviäinen, Reetta, Prof.

University of Eastern Finland
 Department of Neurology
 Kuopio, Finland
 reetta.kalviainen@uef.fi

Kaplan, Peter, Prof.

Johns Hopkins University School of Medicine
 Department of Neurology
 Baltimore, USA
 pkaplan@jhmi.edu

Kapur, Jaideep, Prof.

University of Virginia
 Brain Institute
 Charlottesville, USA
 jk8t@virginia.edu

Kasteleijn-Nolst Trenité, Dorothée, Dr.

University Hospital Utrecht
 Department of Neurosurgery and Epilepsy
 Utrecht, Netherlands
 dkasteleijn@planet.nl

Kellinghaus, Christoph, Prof.

Klinikum Osnabrück
 Department of Neurology and Epilepsy Center
 Osnabrück, Germany
 christoph.kellinghaus@klinikum-os.de

Kluger, Gerhard, Dr.

Schön Klinik
 Fachzentrum für pädiatrische Neurologie, Neuro-Rehabilitation und
 Epileptologie
 Vogtareuth, Germany
 gkluger@schoen-kliniken.de

Kullmann, Dimitri, Prof.

University College London
 UCL Queen Square Institute of Neurology
 London, UK
 d.kullmann@ucl.ac.uk

Lattanzi, Simona, Prof.

Marche Polytechnic University
 Department of Experimental and Clinical Medicine
 Ancona, Italy
 alfierelattanzisimona@gmail.com

Leitinger, Markus, Dr.

Uniklinikum Salzburg
 Department of Neurology
 Salzburg, Austria
 ma.leitinger@salk.at

Leppik, Ilo, Prof.

University of Minnesota
 Department of Neurology and Pharmacy
 Minneapolis, USA
 leppi001@umn.edu

Loddenkemper, Tobias, Prof.

Boston Children's Hospital
 Department of Neurology
 Boston, USA
 tobias.loddenkemper@childrens.harvard.edu

Löscher, Wolfgang, Prof.

Stiftung Tierärztliche Hochschule
 Department of Pharmacology, Toxicology and Pharmacy
 Hannover, Germany
 wolfgang.loescher.ir@tiho-hannover.de

Navarro, Vincent, Dr.

Sorbonne Université
 Department of Neurology
 Paris, France
 vincent.navarro@aphp.fr

Neligan, Aidan, Dr.

University College London
 UCL Queen Square Institute of Neurology
 London, UK
 a.neligan@ucl.ac.uk

Parvizi, Josef, Prof.

Stanford Comprehensive Epilepsy Center
 Department of Neurology
 Stanford, USA
 jparvizi@stanford.edu

Pitkänen, Asla, Prof.

University of Eastern Finland
 A.I. Virtanen Institute for Molecular Sciences
 Kuopio, Finland
 asla.pitkanen@uef.fi

Plecko, Barbara, Prof.

Med Uni Graz
 Department of General Pediatrics
 Graz, Austria
 barbara.plecko@medunigraz.at

Pressler, Ronit, Dr.

Great Ormond Street Hospital for Children
 Department of Clinical Neurophysiology
 London, UK
 r.pressler@ucl.ac.uk

Rogawski, Michael A., Dr.

University of California, Davis
 Department of Neurology
 Sacramento, USA
 rogawski@yahoo.com

Rohde, Eva, Prof.

Uniklinikum Salzburg
 Department of Neurology
 Salzburg, Austria
 e.rohde@salk.at

Rosenow, Felix, Prof.

Goethe University Frankfurt
 Epilepsy Center Frankfurt Rhine-Main,
 Department of Neurology
 Frankfurt, Germany
 rosenow@med.uni-frankfurt.de

Rubboli, Guido, Prof.

University of Copenhagen
 Department of Clinical Medicine
 Dianalund, Denmark
 guru@filadelfia.dk

Shorvon, Simon, Prof.

University College London
 UCL Queen Square Institute of Neurology
 London, UK
 s.shorvon@ucl.ac.uk

Silbergleit, Robert, Prof.

University of Michigan
 Department of Emergency Medicine
 Ann Arbor, USA
 robie@umich.edu

Specchio, Nicola, Prof.

Children's Hospital Bambino Gesù
 Department of Neuroscience
 Rome, Italy
 nicola.specchio@gmail.com

Sutter, Raoul, Prof.

University Hospital Basel
Intensive Care Unit
Basel, Switzerland
raoul.sutter@usb.ch

Sutula, Thomas, Prof.

University of Wisconsin-Madison
Department of Neurology
York, USA
sutula@neurology.wisc.edu

Trinka, Eugen, Prof.

Uniklinikum Salzburg
Department of Neurology
Salzburg, Austria
e.trinka@salk.at

van Putten, Michel, Prof.

University of Twente
Medisch Spectrum Twente
Enschede, Netherlands
m.j.a.m.vanputten@utwente.nl

Vezzani, Annamaria, Prof.

Mario Negri Institute for Pharmacological Research
Department of Neuroscience
Milan, Italy
annamaria.vezzani@marionegri.it

Walker, Matthew, Prof.

University College London
UCL Queen Square Institute of Neurology
London, UK
m.walker@ucl.ac.uk

Wasterlain, Claude, Prof.

David Geffen School of Medicine at UCLA
Department of Neurology
Guilford, USA
wasterla@ucla.edu

Wong, Nora, Dr.

Norse Institute
Department of Neurology
Summit, USA
nora.norse@gmail.com

P01

Aqueous Prodrug/Enzyme Combinations for Intranasal Benzodiazepine Rescue Therapy: Diazepam versus Midazolam ProdrugsSiegel R¹, Rautiola D², Kapoor Bhushan M¹, Cheryala N³, Georg G³, Cloyd J⁴

¹Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, United States, ²Department of Formulation & Process Development, Gilead Sciences, Inc., Foster City, California, United States, ³Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, United States, ⁴Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, United States

P02

Antiseizure Activity of Intranasal Allopregnanolone in Mouse Seizure Threshold TestsZolkowska D¹, Wu C^{1,2}, Rogawski M¹

¹Department of Neurology, School of Medicine, University of California, Davis, Sacramento, United States, ²Bioanalysis and Pharmacokinetics Core Facility, University of California, Davis, Sacramento, United States

P03

Seizures revisited – do astrocytes play an active role in ictogenesis?Heuser K¹, Nome C², Berger T¹, Bakke Buggetun C², Taubøll E¹, Enger R²

¹Department of Neurology, Oslo University Hospital, Oslo, Norway, ²Glia Lab, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

P04

Intramuscular Allopregnanolone for Early Treatment of Status Epilepticus: Pharmacokinetics, Pharmacodynamics, and Safety in DogsPatterson E¹, Vuu I², Wu C³, Zolkowska D³, Leppik I⁴, Rogawski M³, Worrell G⁵, Kremen V⁵, Cloyd J⁴, Coles L⁴

¹University Of Minnesota, Saint Paul, United States, ²Amgen, Thousand Oaks, United States, ³University of California, Davis, United States, ⁴University of Minnesota, Minneapolis, United States, ⁵Mayo Clinic, Rochester, United States

P05

WITHDRAWN

P06

Utilization of Quantitative EEG Spectral Analysis to Characterize IV Ganaxolone PK/PD Properties in Refractory Status Epilepticus (RSE)Vaitkevicius H^{1,2}, Rybak E¹, Meersman M³, an Mierlo P³, Hulihan J¹, Gasior M¹

¹Marinus Pharmaceuticals, Radnor, PA, United States, ²Department of Neurology, Brigham and Women's Hospital, Boston, MA, United States, ³Epilog, Gent, Belgium

P07

Phase 2 Open-Label, Dose-Finding Study of Intravenous Ganaxolone for the Treatment of Refractory Status EpilepticusVaitkevicius H^{1,2}, Ramsay E³, Swisher C⁴, Husain A^{5,6}, Aimetti A¹, Ryback E¹, Gasior M¹

¹Marinus Pharmaceuticals, Radnor, PA, United States, ²Department of Neurology, Brigham and Women's Hospital, Boston, MA, United States, ³Neurosciences Institute, Ochsner Health System, New Orleans, LA, United States, ⁴Carolinas Medical Center, Atrium Health, Charlotte, NC, United States, ⁵Department of Neurology, Duke University, Durham, NC, United States, ⁶Neurodiagnostic Center, Veterans Affairs Medical Center, Durham, NC, United States

P08

Intravenous Formulation of Ganaxolone for the Treatment of Refractory Status Epilepticus: Safety Analysis of the Renal Function in a Phase 2 Open-Label, Dose-Ranging Study

Gasior M¹, Rybak E¹, Ramsay E², Swisher C³, Vaitkevicius H^{1,4}

¹Marinus Pharmaceuticals, Radnor, PA, United States, ²Neurosciences Institute, Ochsner Health System, New Orleans, LA, United States, ³Carolinas Medical Center, Atrium Health, Charlotte, NC, United States, ⁴Department of Neurology, Brigham and Women's Hospital, Boston, MA, United States

P09

Whole exome sequencing in ovarian teratomas in patients with and without NMDAR encephalitis

Jang Y¹, Lee G¹, Park K¹, Lee S¹, Chu K¹, Lee C¹, Won J¹, Lee S¹, Lee H¹

¹Seoul National University Hospital, Seoul, South Korea

P10

Challenges of diagnosing status epilepticus in adult patients with epilepsy and intellectual disabilities: a report of five cases

Peña-Ceballos J^{1,2}, Moloney P^{1,2}, Gibson C¹, O'Donnell C¹, O'Donnell A¹, Delanty N^{1,2}, Widdess-Walsh P^{1,2}

¹Beaumont Hospital, Dublin, Ireland, ²Royal College of Surgeons in Ireland, Dublin, Ireland

P11

Exploratory study of new serum biomarkers related to the diagnosis of Status Epilepticus (SE).

Santamarina Perez E¹, Campos D¹, Abreira L¹, Restrepo-Vera J¹, Quintana M¹, Penalba A², Fonseca E¹, Lallana S¹, Toledo M¹

¹Vall Hebron Hospital - Epilepsy Unit, Barcelona, Spain, ²Vall Hebron Hospital - Neurovascular Laboratory, Barcelona, Spain

P12

FIRES in children: Time not treatment is brain?

Soler Wenglein J¹, Kluger G², van Baalen A¹

¹Klinik für Kinder- und Jugendmedizin II, UKSH, Kiel, Germany, ²Klinik für Neuropädiatrie und Neurologische Rehabilitation, Epilepsiezentrum für Kinder und Jugendliche, Schön Klinik, Vogtareuth, Germany

P13

Prognostic Scores in Status Epilepticus: A Systematic Review and Meta-analysis

Yuan F^{1,2}, Charlotte D¹, Gaspard N¹

¹Université Libre De Bruxelles - Hôpital Universitaire De Bruxelles - Hôpital Erasme, Brussels, Belgium, ²The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

P14

Neuro-glial degeneration in Status Epilepticus: evaluation of serum levels of Neurofilament Light Chains and S100B

Giovannini G^{1,2,3}, Bedin R³, Orlandi N^{1,3}, Turchi G⁴, Cioclu M^{1,3}, Micalizzi E², Biagioli N^{1,3}, Madrassi L^{1,3}, Pugnaghi M¹, Vaudano A^{1,3}, Meletti S^{1,3}

¹Unit of Neurology, OCB Hospital, AOU Modena, Modena, Italy, ²PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Biomedical, Metabolic and Neural Sciences; Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy, ⁴Neurology division, ASL of Modena, Modena, Italy

P15

Management of Status Epilepticus (SE) in adults: a systematic review of Clinical Practice Guidelines (CPGs)

Tontini V¹, Di Vito L², Mazzoni S², Bisulli F^{2,3}, Tinuper P^{2,3}, Vignatelli L⁴

¹Neurology Unit, Department of Medicine and Surgery, Parma, Italy, ²IRCCS Istituto delle Scienze Neurologiche di Bologna, Epilepsy Program, Bologna, Italy, ³Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy, ⁴IRCCS Istituto delle Scienze Neurologiche di Bologna, ISNB – UOSI Epidemiologia e Statistica, Bologna, Italy

P16

The ADAN scale for the identification of status epilepticus: A multicentre prospective study

Restrepo Vera J¹, Sala J², Parejo-Carbonell B³, Ciurans J⁴, Becerra J⁴, Campos D¹, García-Morales I³, Quintana M¹, Santamarina E¹

¹Epilepsy Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ² Epilepsy Unit, Neurology Department, Hospital de Bellvitge, Barcelona, Spain, ³Epilepsy Unit, Neurology Department, Hospital Clínico San Carlos, Madrid, Spain, ⁴ Epilepsy Unit, Neurology Department, Hospital Germans Trias i Pujol, Barcelona, Spain

P17

DOOR-STEP: A Desirability of Outcome Ranking Scale for Clinical Trials of Status Epilepticus Treatment

Chamberlain J¹, Kapur J³, Silbergleit R⁴, Rosenthal E⁵, Elm J⁶, Bleck T⁷, Shinnar S⁸, Zehtabchi S⁹, Evans S¹⁰

¹Children's National Hospital, Washington, DC, United States, ²George Washington University School of Medicine and Health Sciences, Washington, DC, United States, ³University of Virginia, Charlottesville, VA, USA, ⁴University of Michigan, Ann Arbor, MI, USA, ⁵Harvard University and Massachusetts General Hospital, Boston, MA, USA, ⁶Medical University of South Carolina, Charleston, SC, USA, ⁷Northwestern University, Chicago, IL, USA, ⁸Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY, USA, ⁹Downstate Health Sciences University, Brooklyn, NY, USA, ¹⁰George Washington University, Washington, DC, USA

P18

Evaluation of the efficacy of add-on perampanel in focal motor status epilepticus, the PEPSI trial

Navarro V^{1,2}, Hanin A², Freund Y¹, Rheims S³, Demeret S¹

¹Sorbonne Université, Assistance Publique Hôpitaux de Paris, Paris, France, ²Paris Brain Institute, INSERM, CNRS, Paris, France, ³Hospices Civils de Lyon and Lyon 1 University, Bron, France

P19

Comparative efficacy of anti-seizure medications (ASMs) in New-Onset Refractory Status Epilepticus (NORSE) treatment: a multicenter italian real-world study

Dono F¹, Rollo E², Evangelista G¹, Romozzi M², Consoli S¹, Rodorigo D¹, Calabresi P², Sensi S¹, Anzellotti F¹, Vollono C²

¹Department of Neuroscience, Imaging and Clinical Science, "G.d'Annunzio" University of Chieti-Pescara, Chieti, Italy, ²Department of Neurology, Catholic University of the Sacred Heart, Rome, Italy

P20

What biological biomarkers for which purpose?

Hanin A^{1,2}, Lambrecq V^{1,2}, Demeret S¹, Denis J¹, Chavez M², Navarro V^{1,2}

¹Pitié-Salpêtrière Hospital, Paris, France, ²Institut du Cerveau, Paris, France

P21

Hypersynchronous delta wave activity as a characteristic EEG finding of disorder of arousal

Kang M¹, Shin D¹, Lee H¹, Jung K¹

¹Seoul National University Hospital, Jongno-gu, Seoul, South Korea

P22

Non convulsive refractory status epilepticus induced by thiolcolchicoside (TCC) intrathecal injection: a case report.

Evangelista G¹, Dono F¹, Consoli S¹, Pozzilli V¹, Calisi D¹, Russo M¹, D’Orazio C², D’andreaiovanni A², Montesano G², Rapini S², Caulo M¹, Onofrj M¹, Anzellotti F³

¹Department of Neuroscience, Imaging and Clinical Science, “G. D’Annunzio” University of Chieti-Pescara, Chieti, Italy, ²Department of Neurology, “S Spirito” Hospital, Pescara, Italy, ³Department of Neurology, Epilepsy Center, “SS Annunziata” Hospital, Chieti, Italy

P23

Autonomic Status Epilepticus in a Patient with Parasellar Meningioma: A Case Report

Corniello C¹, Dono F¹, Consoli S¹, Evangelista G¹, Onofrj M¹, Sensi S^{1,2,3}, Anzellotti F¹

¹Department of Neuroscience, Imaging and Clinical Science, University “G. D’Annunzio”, Chieti-Pescara, Italy, ²Behavioral Neurology and Molecular Neurology Units, Center for Advanced Studies and Technology - CAST-, University G. d’Annunzio of Chieti-Pescara, Italy, Chieti-Pescara, Italy, ³Institute for Mind Impairments and Neurological Disorders - iMIND, University of California, Irvine, USA

P24

Tumor-associated status epilepticus (TASE) in patients with low-frequency Periodic Discharges (PDs): a case series

Consoli S¹, Dono F¹, Evangelista G¹, Corniello C¹, Onofrj M¹, Sensi S^{1,2,3}, Anzellotti F¹

¹Department of Neuroscience, Imaging and Clinical Science, University “G. D’Annunzio”, Chieti-Pescara, Italy, ²Behavioral Neurology and Molecular Neurology Units, Center for Advanced Studies and Technology - CAST-, University G. d’Annunzio, Chieti-Pescara, Italy, ³Institute for Mind Impairments and Neurological Disorders - iMIND, University of California, Irvine, USA

P25

The practices and priorities in status epilepticus care from the perspective of health care professionals in Low- and Middle-income countries-a cross sectional study

Marshall C, Olaniyan T, Kifewew S, Zaman Soomro M, Rupasinghe P, Mwamba S, Chigamba S, Ranglin Edwards G, Kinney M

¹University of Dundee, Dundee, Scotland, ²Pretola Global Health and Consulting, UK, ³Addis Abba University, Addis Abba, Ethiopia, ⁴Neurology Department, Peoples Medical College & Hospital, Pakistan, ⁵Ministry of Health, Colombo, Sri Lanka, ⁶Kemri Welcome Trust, Kenya, ⁷Foundation of Epilepsy Warriors, Malawi, ⁸Jamaica Defence Force, Jamaica, ⁹Belfast Health and Social Care Trust, Belfast, UK

P26

A consensus guideline on the emergency management of seizures: a step towards a „seizure code“

Garcia Morales I^{1,2}, Fernández Alonso C³, Behzadi Koochani N⁴, Serratosa Fernández J⁵, Gil-Nagel A², Toledo Argany M⁶, López González F⁷, Santamarina Pérez E⁶

¹Servicio Neurología, Unidad de Epilepsia, Hospital Clinico San Carlos, MADRID, Spain, ²Programa Epilepsia. Servicio Neurología Hospital Ruber Internacional, MADRID, Spain, ³Servicio Urgencias, Hospital Clinico San Carlos, Madrid, Spain, ⁴Servicio de Urgencias Médicas de La comunidad de Madrid SUMMA112, MADRID, Spain, ⁵Servicio Neurología, Unidad Epilepsia, Hospital Universitario Fundación Jiménez Díaz, MADRID, Spain, ⁶Servicio Neurología, Unidad de Epilepsia, Hospital Vall d’Hebron, BARCELONA, SPAIN, ⁷Servicio Neurología, Unidad de Epilepsia, Hospital General de Santiago de Compostela, SANTIAGO DE COMPOSTELA, SPAIN

P27

Anti-LGI1 encephalitis following COVID-19 vaccination: a case series

Asioli G¹, Muccioli L², Barone V², Spinardi L¹, Mastrangelo V³, Bernabè G³, Longoni M⁴, Bisulli F¹, Tinuper P¹, Guarino M¹, Cortelli P¹

¹ISNB Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, ²Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy, ³Neurology Unit, Rimini "Infermi" Hospital, AUSL Romagna, Rimini, Italy, ⁴Neurology and Stroke Unit, Department of Neuroscience, "Maurizio Bufalini" Hospital, Cesena, Italy

P28

Clinical features and outcome of Status Epilepticus in the elderly: data from the population of Modena, northern Italy.

Orlandi N^{1,2}, Giovannini G^{1,3}, Turchi G⁴, Cioclu M^{1,2}, Biagioli N^{1,2}, Madrassi L^{1,2}, Micalizzi E³, Pugnaghi M¹, Vaudano A^{1,2}, Meletti S^{1,2}

¹Neurology Unit, OCB Hospital, AOU Modena, Modena, Italy, ²Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁴Neurology division, ASL of Modena, Modena, Italy

P29

Outcome of Status Epilepticus in ICU

Damien C¹, Gaspard N¹

¹CUB Erasme - ULB, Brussels, Belgium

P30

"It's not mine!" First description of non-convulsive status epilepticus manifesting with somatoparaphrenia

Nucera B¹, Rinaldi F¹, Flore D¹, Bratti A¹, Nardone R¹, Brigo F¹

¹Franz Tappeiner Hospital, Merano, Italy

P31

First description of lingual focal motor status epilepticus due to ischemic stroke

Nucera B¹, Rinaldi F¹, Flore D¹, Bratti A¹, Nardone R¹, Brigo F¹

¹Franz Tappeiner Hospital, Merano, Italy

P32

Status of continuous epileptic spasms possibly provoked by VNS battery depletion and resolved by its replacement.

Pondrelli F¹, Di Vito L², Martinoni M², Stipa C², Bisulli F^{1,2}, Boni A², Licchetta L², Alvisi L^{1,2}, Tinuper P^{1,2}, Mostacci B²

¹DIBINEM Dipartimento di Scienze Biomediche e Neuromotorie, University Of Bologna, Bologna, Italy, ²IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

P33

External validation of STESS and EMSE to predict mortality: a machine-learning analysis

Brigo F¹, Turcato G², Lattanzi S³, Orlandi N^{4,5}, Turchi G⁴, Zaboli A⁶, Giovannini G⁷, Meletti S^{4,5}

¹Hospital of Merano (SABES-ASDAA), Department of Neurology, Merano, Italy,

²Hospital of Santorso (AULSS-7), Department of Internal Medicine, Santorso, Italy,

³Marche Polytechnic University, Neurological Clinic, Department of Experimental and Clinical Medicine, Ancona, Italy, ⁴Azienda Ospedaliera-Universitaria di Modena, Neurology Department, Modena, Italy, ⁵University of Modena and Reggio-Emilia, Department of Biomedical, Metabolic, and Neural Sciences, Modena and Reggio-Emilia, Italy, ⁶Hospital of Merano-Meran (SABES-ASDAA), Department of

Emergency Medicine, Merano, Italy, ⁷University of Modena and Reggio-Emilia, PhD program in Clinical and Experimental Medicine, Modena, Italy

P34

An Empiric Approach Guiding Subanesthetic Ketamine Dosing for Patients with Established Status Epilepticus

Barra M¹, Coles L², Tan C³, Kapur J⁴, Chamberlain J⁵, Silbergleit R⁶, Goldstein J⁷, Hayes B¹, Bleck T⁸, Sharma G⁹, Cole A⁹, Shinnar S¹⁰, Cloyd J², Rosenthal E⁹

¹Department of Pharmacy, Massachusetts General Hospital, Boston, MA, United States, ²Department of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, United States, ³Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Charlestown, MA, United States, ⁴Department of Neurology, University of Virginia, Charlottesville, VA, United States, ⁵Division of Emergency Medicine, Children's National Hospital, Washington, DC, United States, ⁶Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, United States, ⁷Department of Emergency Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States, ⁸Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States, ⁹Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States, ¹⁰Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, United States

P35

WITHDRAWN

P36

Hyper-perfusion Tmax mapping for non-convulsive status epilepticus in the acute setting: a pilot case-control study

Muccioli L¹, Romoli M², Merli E³, Galluzzo S³, Testoni S³, Zaniboni A³, Contardi S³, Simonetti L³, Tinuper P^{1,3}, Zini A³

¹Department of Biomedical and Neuromotor Sciences, University Of Bologna, Bologna, Italy, ²Neurology and Stroke Unit, Bufalini Hospital, Cesena, Italy, ³IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

P37

EEG seizures onset patterns and duration in focal status epilepticus

Turchi G¹, Giovannini G^{1,2}, Melegari G³, Orlandi N^{1,4}, Cioclu M^{1,4}, Avanzini I⁴, Vaudano A¹, Meletti S^{1,4}

¹Neurology Department, Azienda ospedaliera-Universitaria di Modena, Modena, Italy, ²PhD program in Clinical and Experimental Medicine University of Modena and Reggio Emilia, Modena, Italy, ³Intensive Care Unit, Azienda Ospedaliera-Universitaria, Modena, Italy, ⁴Dept of Biomedical, Metabolic, and Neural Sciences, University of Modena, Modena, Italy

P38

Recurrent non-convulsive status epilepticus in the elderly: a case of unknown etiology but steroid responsiveness

Falcicchio G¹, Trojano M¹, La Neve A¹

¹Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy

P39

Sustained hyperperfusion after status epilepticus: a neuroimaging ICTAL-INTERICTAL continuum?

Sala Pradó J¹, Reynes G¹, Jaraba S¹, Mora J¹, Pedro J¹, Veciana M¹, Garcia-Parra B¹, Falip M¹

¹Hospital Universitari De Bellvitge, Hospitalet De Llobregat, Spain

P40

Predicting the progression to super-refractory status epilepticus: a machine-learning study

Brigo F¹, Turcato G², Lattanzi S³, Orlandi N⁴, Turchi G⁵, Zaboli A¹, Giovannini G⁵, Meletti S⁴

¹Hospital of Merano, Merano, Italy, ²Hospital of Santorso, Santorso, Italy, ³Marche Polytechnic University, Ancona, Italy, ⁴University of Modena and Reggio Emilia, Modena, Italy, ⁵Azienda Ospedaliera-Universitaria di Modena, Modena, Italy

P41

Ketamine to treat refractory and super refractory status epilepticus: Experience of two centers

Parejo Carbonell B¹, García M¹, Mayo P¹, Rodrigo M², Romeral M¹, Campos D², Pardo C¹, Santamarina E², García-Morales I¹

¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Vall d'Hebron, Barcelona, Spain

P42

Bitemporal Epileptiform Abnormalities following Maintenance Electroconvulsive Therapy: A Case Report

Wadi L¹, Parikh P¹

¹Duke University Hospital, Durham, United States

P43

Factors associated with status epilepticus mortality in Colombia

Ayala Castillo M¹, Rojas J¹, Vergara J^{1,2}

¹Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia, ²Hospital de San José, Bogotá, Colombia

P44

Factors contributing to case fatality rate in patients with status epilepticus – Data from a prospective observational registry (SENSE)

Kellinghaus C¹, Rüegg S², Rossetti A³, Trinka E⁴, Unterberger I⁵, Sutter R², Strzelczyk A⁶, Tilz C⁷, Uzelac Z⁸, Rosenow F⁶

¹Klinikum Osnabrück, Osnabrück, Germany, ²University Hospital Basel, Basel, Switzerland, ³CHUV and University of Lausanne, Lausanne, Switzerland, ⁴Christian Doppler Klinik and Paracelsus Medical University, Salzburg, Austria, ⁵Innsbruck Medical University, Innsbruck, Austria, ⁶Dept. of Neurology and Epilepsy Center, University of Frankfurt, Frankfurt, Germany, ⁷Hospital Barmherzige Brüder Regensburg, Regensburg, Germany, ⁸University of Ulm, Ulm, Germany

P45

WITHDRAWN

P46

Long-term survival after status epilepticus is predicted by age, level of consciousness at admission, and duration: validation of the ACD-score

Roberg L¹, Monsson O¹, Kristensen S¹, Dahl S¹, Ulvin L², Heuser K², Taubøll E², Bechert L⁴, Knake S⁴, Rosenow F³, Strzelczyk A³, Beier D¹, Beniczky S⁵, Krøigård T¹, Beier C¹

¹Odense University Hospital, Odense, Denmark, ²Department of Neurology, Oslo University Hospital, Oslo, Norway, ³Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University Frankfurt, Frankfurt am Main, Germany, ⁴Epilepsy Center Hessen and Department of Neurology, Philipps-University, Marburg, Germany, ⁵Danish Epilepsy Center, Dianalund, Denmark

P47

Prognosis of status epilepticus: Relationship between delayed treatment and subsequent development of epilepsy

Rodrigo-Gisbert M¹, Gómez-Dabó L¹, Quintana M¹, Campos-Fernández D¹, Gifreu A¹, Fonseca E¹, Abreira L¹, Toledo M¹, Santamarina E¹

¹Epilepsy Unit, Neurology Department. Hospital Universitari Vall d'Hebron, Barcelona, Spain

P48

Out-of-hospital versus in-hospital status epilepticus: the role of etiology and comorbidities

Orlandi N^{1,2}, Giovannini G^{1,3}, Turcato G⁴, Lattanzi S⁵, Turchi G⁶, Zaboli A⁷, Brigo F⁸, Meletti S^{1,2}

¹Neurology Unit, OCB Hospital, AOU Modena, Modena, Italy, ²Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁴Hospital of Santorso (AULSS-7), Department of Internal Medicine, Santorso, Italy, ⁵Marche Polytechnic University, Neurological Clinic, Department of Experimental and Clinical Medicine, Ancona, Italy, ⁶Neurology division, ASL of Modena, Modena, Italy, ⁷Hospital of Merano-Meran (SABES-ASDAA), Department of Emergency Medicine, Merano-Meran, Italy, ⁸Hospital of Merano-Meran (SABES-ASDAA), Department of Neurology, Merano-Meran, Italy

P49

Survival in post-hypoxic encephalopathy after cardiopulmonary resuscitation: Role of repetitive EEGs, epileptiform discharges, seizure and status patterns

Strzelczyk A¹, Siebenbrodt K¹, Strüber M¹, Beuchat I², Knake S³, Rosenow F¹, Schieffer B³, Karatolios K³, Willems L¹

¹Goethe-University Frankfurt, Frankfurt Am Main, Germany, ²Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, ³Philipps-University Marburg, Marburg, Germany

P50

Curative Surgery for Super refractory Status epilepticus

Kalra V¹, Kaur U¹, Relhan S¹, Singh G

¹Dayanand Medical College And Hospital, Ludhiana, Ludhiana, India

P51

Outcome in patients with de novo status epilepticus

Kuchukhidze G^{1,2,3}, Bosque Varela P^{1,2}, Machegger L³, Steinbacher J³, Oellerer A³, Prüwasser T^{1,4}, Zimmermann G^{4,5,6}, Pfaff J³, McCoy M^{1,3}, Trinka E^{1,2,7}

¹Department of Neurology, Member of the European Reference Network EpiCARE, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria, ²Neuroscience Institute, Christian Doppler University Hospital, Salzburg, Austria, ³Department of Neuroradiology, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria, ⁴Department of Mathematics, Paris-Lodron University, Salzburg, Austria, ⁵Team Biostatistics and Big Medical Data, IDA Lab Salzburg, Paracelsus Medical University, Salzburg, Austria, ⁶Research and Innovation Management, Paracelsus Medical University, Salzburg, Austria, ⁷Karl Landsteiner Institute for Neurorehabilitation and Space Neurology, Salzburg, Austria

P52

Prediction of long-term mortality after Status Epilepticus using clinical scoring systems

Gomez Dabo L¹, Rodrigo-Gisbert M¹, Quintana M¹, Campos-Fernández D¹, Gifreu A¹, Fonseca E¹, Abreira L¹, Toledo M¹, Santamarina E¹

¹Epilepsy Unit, Neurology Department. Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

P53

Ictal-interictal continuum – the role of MRI in the diagnosis of status epilepticus

Bosque Varela P¹, Machegger L², Oellerer A², Steinbacher J², McCoy M^{1,2}, Pfaff J², Trinka E^{1,3,4}, Kuchukhidze G^{1,3}

¹Department of Neurology, Christian Doppler University Hospital, Member of the European Reference Network EpiCARE, Centre for Cognitive Neuroscience, Paracelsus Medical University, Salzburg, Austria, ²Department of Neuroradiology, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria, ³Neuroscience Institute, Christian Doppler University Hospital, Salzburg, Austria, ⁴Karl Landsteiner Institute for Neurorehabilitation and Space Neurology, Salzburg, Austria

P54

Can an EEG pattern predict the risk of developing peri-ictal MRI abnormalities in status epilepticus?

Machegger L¹, Bosque Varela P², Steinbacher J¹, Oellerer A¹, Prüwasser T^{2,3}, Zimmermann G^{3,4,5}, Pfaff J¹, McCoy M^{1,2}, Trinka E^{2,6,7}, Kuchukhidze G^{2,6}

¹Department of Neuroradiology, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria, ²Department of Neurology, Christian Doppler University Hospital, Member of the European Reference Network EpiCARE, Centre for Cognitive Neuroscience, Paracelsus Medical University, Salzburg, Austria, ³Department of Mathematics, Paris-Lodron University, Salzburg, Austria, ⁴Team Biostatistics and Big Medical Data, IDA Lab Salzburg, Paracelsus Medical University, Salzburg, Austria, ⁵Research and Innovation Management, Paracelsus Medical University, Salzburg, Austria, ⁶Neuroscience Institute, Christian Doppler University Hospital, Salzburg, Austria, ⁷Karl Landsteiner Institute for Neurorehabilitation and Space Neurology, Salzburg, Austria

P55

Knowledge regarding status epilepticus among medical-surgical specialties residents in Colombia

Ortega L, Vergara J, Dueñas F, Cuesta A

P56

Intravenous topiramate as an alternative treatment of seizures during pregnancy: A case report

Apostolakopoulou L^{1,2}, Bosque-Varela P², O'Sullivan C², Rossini F², Löscher W^{3,4}, Kuchukhidze G^{2,5}, Trinka E^{2,5,6}

¹First Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece, ²Department of Neurology, Christian Doppler University Hospital, Centre for Cognitive Neuroscience, Member of the European Reference Network EpiCARE, Paracelsus Medical University, Salzburg, Austria, ³Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, Hannover, Germany, ⁴Center for Systems Neuroscience, Hannover, Germany, ⁵Neuroscience Institute, Christian Doppler University Hospital, Centre for Cognitive Neuroscience, Salzburg, Austria, ⁶Karl Landsteiner Institute for Neurorehabilitation and Space Neurology, Salzburg, Austria

P57

FADD gene pathogenic variants causing recurrent febrile infection-related epilepsy syndrome

Giovannini G^{1,2,3}, Procopio E⁴, Giannoccaro M⁵, Cioclu M^{1,3}, Liguori R⁵, Guerrini R⁶, Meletti S^{1,3}

¹Unit of Neurology, OCB Hospital, AOU Modena, Modena, Italy, ²PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Biomedical, Metabolic and Neural Sciences; Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy, ⁴Inborn Metabolic and Muscular Disorders Unit, Anna Meyer Children's Hospital, Florence, Italy, ⁵IRCCS, Bellaria Hospital, Bologna, Italy, ⁶Pediatric Neurology, Neurogenetics, and Neurobiology Unit and Laboratories, Anna Meyer Children's Hospital, Florence, Italy

P58

Autoimmune-associated epilepsy as the outcome of autoimmune encephalitis with NORSE presentation

Matricardi S¹, Casciato S², Deleo F³, Freri E⁴, Stabile A³, Meletti S⁵, Giovannini G⁵, Zucchi E⁵, Mariotto S⁶, Bozzetti S⁶, Ferrari S⁶, Sartori S⁷, Nosadini M⁷, Cesaroni E¹, Marini C¹, Di Bonaventura C⁸, Di Gennaro G², Gambardella A⁹, Zuliani L¹⁰, Zoccarato M¹¹, Pasini E¹², Michelucci R¹², Vogrig A¹³, Pualetto G¹³, Belcastro V¹⁴, Zinno L¹⁵, Liguori C¹⁶, Ferretti A¹⁷, Santarone M¹⁷, Fusco L¹⁷, Granata T⁴, Villani F¹⁸

¹Child Neurology and Psychiatry Unit, Children's Hospital "G. Salesi", Ospedali Riuniti Ancona, Ancona, Italy, ²IRCCS Neuromed, Pozzilli, Italy, ³Epilepsy Unit, Fondazione IRCCS Carlo Besta Neurological Institute, Milan, Italy, ⁴Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, ⁵Dept of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio-Emilia, Modena, Reggio Emilia, Italy, ⁶Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy, ⁷Paediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy, ⁸Epilepsy Unit, Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy, ⁹Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy, ¹⁰Department of Neurology, Ospedale San Bortolo, Azienda ULSS8 Berica, Vicenza, Italy, ¹¹Neurology Unit O.S.A. - Azienda Ospedale Università Padova, Padova, Italy, ¹²Unit of Neurology, IRCCS - Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, ¹³Department of Neurosciences, Santa Maria della Misericordia University Hospital, Udine, Italy, ¹⁴Neurology Unit, Maggiore Hospital, Lodi, Italy, ¹⁵Neurology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy, ¹⁶Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, ¹⁷Department of Neuroscience, Children's Hospital Bambino Gesù, Rome, Italy, ¹⁸Division of Clinical Neurophysiology and Epilepsy Centre, IRCCS Ospedale Policlinico San Martino, Genova, Italy

P59

Prognostic value of EEG patterns in comatose patients with resuscitated cardiac arrest

Misirocchi F¹, Florindo I¹, Mannini E¹, Iazzari S¹, Tontini V¹, Zilioli A¹, Zinno I¹, Parrino L¹, Bernabè G¹

¹University Of Parma, unit of Neurology, Parma, Italy

P60

Ependymal Cyst with Unusual Presentation: A Rare Cause of Status Epilepticus

Sharkova S¹, Kopachev D¹, Petrosyan D¹

¹Research Center Of Neurology, Moscow, Russia, Moscow, Russian Federation

P61

Correlation between serum and cerebrospinal fluid levels of tau protein in patients with non-refractory, refractory, and super-refractory convulsive status epilepticus

Alvarado M¹, León M², Orozco S³, Marquez M⁴, Hernández L⁵

¹Hospital De Alta Especialidades La Raza, Ciudad De Mexico, Mexico, ²Hospital de Alta Especialidades La Raza, Ciudad de Mexico, Mexico, ³Hospital siglo XXI, Ciudad de Mexico, Mexico, ⁴Hospital de Alta Especialidades La Raza, Ciudad de Mexico, Mexico, ⁵Hospital de Alta Especialidades La Raza, Ciudad de Mexico, Mexico

P62

Cumulative Plasma Concentration Exposure, Not Singular Concentrations, Best Explains Brivaracetam/Levetiracetam Correlation for to Photoparoxysmal Response Elimination in Patients with Photosensitive Epilepsy: Updated Exploratory Results from a Randomized, Double-blind, Crossover Study

Reed R¹, Kasteleijn Nolst-Trenite' D², Rosenfeld W³, Lippmann S³

¹West Virginia University, Morgantown, United States, ²Utrecht Medical Center, Utrecht, The Netherlands, ³Comprehensive Epilepsy Center, St. Louis, USA

P63

The Incidence of Suspected Epileptic Seizures – a Population-based Study

Kämppi L¹, Puolakka T^{2,3}, Ritvanen J⁴, Tuppurainen K⁴, Pääkilä J⁵, Kuisma M², Peltola J⁶

¹Epilepsia Helsinki, Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ²Department of Emergency Medicine & Services, Helsinki University Hospital and the University of Helsinki, Helsinki, Finland, ³Department of Anesthesiology & Intensive Care Medicine, Helsinki University Hospital and the University of Helsinki, Helsinki, Finland, ⁴Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ⁵Department of Mathematical Sciences, University of Oulu, Oulu, Finland, ⁶Department of Neurology, Tampere University Hospital and University of Tampere, Tampere, Finland

P64

The gap and underdose of benzodiazepine drugs in status epilepticus treatment in China: a retrospective cohort study

Peng W¹, Lu L¹, Zhou Y¹, Li J¹, Tian L¹, Zhou D¹

¹West China Hospital, Sichuan University, Chengdu, China

P65

The New-Onset Refractory Status Epilepticus (NORSE/FIRES) Family Registry

Kazazian K¹, Gaspard N², Hirsch L³, Kellogg M⁴, Hocker S⁵, Wong N⁶, Farias-Moeller R⁷, Eschbach K⁸, Gofton T¹

¹Western University, London, Canada, ²Université Libre de Bruxelles–Hôpital Erasme, Brussels, Belgium, ³Yale Comprehensive Epilepsy Center, New Haven, USA, ⁴Oregon Health and Science University, Portland, USA, ⁵Mayo Clinic, Rochester, USA, ⁶NORSE Institute, Summit, USA, ⁷Medical College of Wisconsin, Milwaukee, USA, ⁸Children's Hospital Colorado, Aurora, USA

P66

Intrathecal dexamethasone for the treatment of a child with febrile infection-related epilepsy syndrome (FIRES)

Sawdy R¹, Howe C², Mehta N¹, Farias-Moeller R¹

¹Medical College Of Wisconsin, Milwaukee, Wisconsin, United States, ²Mayo Clinic, Rochester, Minnesota, United States

P67

From Cryptogenic New-Onset super-Refractory Status Epilepticus to Creutzfeldt-Jakob disease

Massot Cladera M¹, Martínez García A¹, Filgueira Dominguez M², Barceló Artiguez M¹, Bargay Bizarro E¹, Jorge V¹, Leal Rullan T, Martin Pena ¹

¹Hospital Universitario Son Espases, Palma De Mallorca, Spain, ²Hospital Comarcal de Inca, Inca, Spain

P68

Non convulsive status epilepticus associated with newly diagnosed MELAS. A clinical, electroencephalographic and radiological case series

Rossini F¹, Kuchukhidze G¹, Pilar B¹, Machegger L², Trinkka E¹

¹Department of Neurology Christian Doppler University Hospital, Salzburg, Austria, ²Department of Radiology Christian Doppler University Hospital, Salzburg, Austria

We wish to acknowledge the generous financial support by the institutions and companies listed below:

MAIN SPONSOR



SAPPHIRE SPONSORS



SPONSORS



GET-TOGETHER

SUNDAY, SEPTEMBER 18TH, 2022

18.40 – 19.30

A get-together at Salzburg Congress will take place after the first day of the Colloquium. We cordially invite you to have a toast to the Colloquium together with your colleagues.
Individual dinners can be planned afterwards.

COLLOQUIUM DINNER ZISTELALM

MONDAY, SEPTEMBER 19TH, 2022

19.00 – 24.00

The conference dinners at the Status Epilepticus Colloquia are famously entertaining. This time, the dinner is being held at the Zistelalm – located on the Gaisberg, Salzburg’s local mountain. Once you reach the top of the Zistelalm, the view of the countryside widens. The Zistelalm enchants with its rural charm surrounded by wonderful nature. At the Zistelalm Stadl an enjoyable and entertaining atmosphere is guaranteed; and all delegates are invited to join the faculty to celebrate the spirit of our Colloquium.

Tickets have to be booked in advance!
Please contact our PCO for remaining tickets: status@cmi.at



Shuttle: Shuttle service starts from Salzburg Congress at 19.00
Dress code: smart casual
Web: <https://www.zistelalm.at/en/>

CONGRESS VENUE

Salzburg Congress
Auerspergstraße 6, 5020 Salzburg, Austria
www.salzburgcongress.at

REGISTRATION DESK

The registration will be located on the 1st floor of the congress centre.
During opening hours you can reach us on: +43 512 5936 1165

Registration cEEG-Course

Saturday, September 17th: 08:00 - 10:00

Pre-registration Colloquium

Saturday, September 17th: 15:00 - 17:00

Registration Colloquium

Sunday, September 18th: 09:00 - 18:00

Monday, September 19th: 08:00 - 18:00

Tuesday, September 20th: 08:00 - 17:00

CONGRESS ORGANISERS

PCO Tyrol Congress
Rennweg 3, 6020 Innsbruck
T: +43 512 575600
E: status@cmi.at



CERTIFICATE OF ATTENDANCE

All registered delegates receive an official certificate of attendance after the conference by email together with a survey about the colloquium.


TRADE EXHIBITION

A trade exhibition of pharmaceutical companies and manufacturers of medical equipment is held next to the plenary room.

EXHIBITION ORGANISERS

S12! studio 12 GmbH
Kaiser Josef Straße 9, 6020 Innsbruck
T: +43-(0)512-890438,
E: office@studio12.co.at





**THE
9TH LONDON-INNSBRUCK
COLLOQUIUM
ON STATUS EPILEPTICUS
AND ACUTE SEIZURES**

**APRIL 26 – 28, 2024
LONDON, UK**

**HELD UNDER THE AUSPICES OF
THE ILAE BRITISH CHAPTER**

SAVE THE DATE

WWW.STATUSPILEPTICUS.EU

CPD CREDITS

The 8th London-Innsbruck Colloquium and 2nd International Teaching Course on Continuous EEG in ICU have been accredited by the Austrian Medical Association for continuous medical education:

Continuous EEG in ICU-Course on September 17th 2022:
ID 746595: 9 CPD credits

8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures (September 18th to 20th):
ID 747153: 29 CPD credits

WIFI

A free WiFi connection is available at the congress centre:
Network: Salzburg Congress
Password: congress1701

COFFEE BREAKS AND REFRESHMENTS

Coffee and tea will be served during the official coffee breaks. Light lunches will be served during the lunch breaks.

CURRENCY

The official currency in Austria is the Euro. Major credit cards are accepted in most hotels, shops and restaurants. Automatic teller machines (ATMs) are available throughout the city.

NAME BADGES

All registered participants receive a name badge together with their registration documents. Please make sure to wear your badge at all times while attending the meeting, exhibition and social events.

LIABILITY AND INSURANCE

Neither the organisers, nor the congress secretariat or other suppliers accept liability for personal injuries or loss or damage of property belonging to congress delegates, either during or as a result of the Congress or during any of the excursion tours. It is recommended that participants arrange for their own personal health, accident and travel insurance.





There is always more to be done

Our commitment to improving the lives of people with severe diseases runs deep. Our work doesn't stop when we close the lab door or analyse the last sample. Always looking for the next discovery, the next innovation – now and into the future.



Inspired by patients.
Driven by science.